DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Sofen H, Smith S, Matheson RT. et al.
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response
in patients with moderate-to-severe psoriasis.
J Allergy Clin Immunol 2014;
133: 1032-1040
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.